Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

ZW25 administered IV once weekly, once every 2 weeks, or once every 3 weeks. Part 1: in multiple increasing doses; Part 2: ZW25 given at the MTD, OBD, or an RD identified in Part 1; Part 3: ZW25 given at the MTD, OBD, or an RD combined with one of the following selected drug combination:

Combination therapy with ZW25 - Part 3 Treatment Groups 1 and 4

Combination therapy with ZW25 - Part 3 Treatment Groups 2 and 5

Combination therapy with ZW25 - Part 3 Treatment Groups 3 and 6

Combination therapy with ZW25 and Capecitabine - Part 3 Treatment Group 7

Combination therapy with ZW25 - Part 3 Treatment Group 8 (may be opened if recommended by the Safety Monitoring Committee and/or the sponsor)